Prosecution Insights
Last updated: August 16, 2026
Application No. 19/249,149

STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF

Non-Final OA §103§112
Filed
Jun 25, 2025
Priority
Apr 23, 2024 — divisional of 12/343,427
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nivagen Pharmaceuticals Inc.
OA Round
3 (Non-Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
2y 8m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
417 granted / 902 resolved
-13.8% vs TC avg
Strong +22% interview lift
Without
With
+22.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
33 currently pending
Career history
955
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.7%
+2.7% vs TC avg
§102
22.1%
-17.9% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 902 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/20/2026 has been entered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim is 13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. For claim 13 the examiner did not find support for the recited stability over 1 month as claimed. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-3,7-17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kumar et al. (WO 2022/058988 A1), in view of Serdons et al. “The Presence of Ethanol in Radiopharmaceutical Injections” Journal of Nuclear Medicine December 2008, 49 (12) 2071. For the reasons set forth in the previous office action filed 11/20/ 2025. Response to Arguments Applicant's arguments filed 4/20/2026 have been fully considered but they are not persuasive. Applicants assert with regard to the new matter rejection that table 7 shows a value of 98.5 percent which they believe shows support for at least 95 percent. This is not persuasive; the narrow data point does not support the broader range. With regard to the prior art Kumar applicants claim the reference teaches hypotonic solutions and prefers their use for stability. As noted in related application 19/240,149, the Serdons reference was provides evidence that solutions with up to 1.35 % ethanol were isotonic. Kumar clearly teaches ethanol in amounts of only 1 wt%, thus teaching isotonic solutions when ethanol is 1 wt%. Since the compositions of Kumar are within the scope of the claimed invention the examiner must presume it will have the same properties. Applicants provide no evidence outside of opinion that the solutions of Kumar are not necessarily stable or isotonic as claimed. An unsupported allegation cannot be considered persuasive. Furthermore, as noted in the previous action Kumar discloses ethanol free solutions and applicants have not provided evidence that the amounts of other ingredients such as dextrose would necessarily result in an isotonic solution. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/ Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Jun 25, 2025
Application Filed
Aug 04, 2025
Non-Final Rejection mailed — §103, §112
Nov 03, 2025
Response Filed
Nov 20, 2025
Final Rejection mailed — §103, §112
Mar 20, 2026
Response after Non-Final Action
Apr 20, 2026
Request for Continued Examination
Apr 22, 2026
Response after Non-Final Action
Apr 27, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12685779
COMPLEX
1y 4m to grant Granted Jul 21, 2026
Patent 12673104
CLEAVABLE POLYMER DRUG CONJUGATES
7y 6m to grant Granted Jul 07, 2026
Patent 12673121
RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGING
2y 7m to grant Granted Jul 07, 2026
Patent 12653911
STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS
4y 4m to grant Granted Jun 16, 2026
Patent 12649008
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
3y 0m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
68%
With Interview (+22.1%)
3y 10m (~2y 8m remaining)
Median Time to Grant
High
PTA Risk
Based on 902 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month